Sharps Tech (STSS): רווח למניה בשנים עשר החודשים האחרונים

Sharps Technology, Inc. (STSS) is developing protective injection systems for hospitals, complemented by a strategic bet on global demand for sterility and the commercial launch of premium syringes. Net income per share over 12 months on GURU.Markets demonstrates the viability of the model, where the current mark equals -8.26, although risks are increasing due to reliance on polymer imports and logistical disruptions.

This indicator measures real capital efficiency by allocating total annual net income per common share to assess the fundamental value of the business. By analyzing the current EPS TTM level, an investor determines the ability of Sharps Technology, Inc. (STSS) to monetize innovative safe injection systems and minimize drug waste through the implementation of specialized syringes.